Press Release FeedGet the RSS feed
Menu

Business Wire

Anthem Blue Cross and Blue Shield Foundation Launches Impact Investment Fund to Strengthen Ohio Communities

Business Wire

New program will deploy capital to mission-driven businesses and nonprofits addressing health-related social needs

COLUMBUS, Ohio, August 26, 2026--The Anthem Blue Cross and Blue Shield Foundation, the charitable arm of Anthem Blue Cross and Blue Shield, launched a new program that deploys capital into mission-driven organizations working to improve health-related social needs.

Established as the Impact Investing Program, this fund focuses on investments in hyper-local, innovative solutions that support mental health, individuals with disabilities or health challenges, housing, food, transportation, access to care, and other social health factors.

"Creating healthier communities starts with investing in the organizations already making a difference for Ohioans," said Jane Peterson, president of Anthem Blue Cross and Blue Shield in Ohio. "Through impact investing, we're helping local nonprofits and small businesses expand their reach, strengthen communities, and improve health and economic opportunities across Ohio."

Through the program, the Foundation will provide access to inclusive and lower-cost financing via loans with interest rates below prime rates to small businesses, social enterprises, and nonprofits tackling unmet health-related social needs. Potential recipients include organizations focused on the following efforts:

  • Improving social health factors, including housing stability and accessibility, healthy food production, access and security, transportation, social connection, digital health, culturally competent care, or economic opportunity.

  • Supporting individuals with disabilities or health challenges through accessible services, adaptive technologies, or inclusive environments that can provide holistic support and services such as vocational training, life skills, community-based health interventions, and employment opportunities.

  • Addressing behavioral and mental health needs, especially with trauma-informed or community-centered programs outside of the traditional provider models. This category seeks local, community-based organizations that strive to expand access to behavioral healthcare through services and workforce training.

As part of its launch in Ohio, the Foundation is partnering with Mission Driven Finance to provide low-interest loans with repayment terms ranging from one to five years. Funds can be used to hire staff, manage payroll, upgrade facilities, purchase equipment, cover rent and utilities, refinance high-interest debt, or provide bridge financing while awaiting contract or grant payments. As loans are repaid, funds are reinvested to support additional organizations, creating a sustainable cycle of community investment.

  1. ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of RecurrenceInterim analysis results from the Phase III DASL-HiCaP trial show a statistically significant 58% reduction in the risk of metastasis or death with NUBEQA® (darolutamide) versus placebo in addition to androgen deprivation therapy (ADT) and radiation therapy (hazard ratio [HR] 0.42; 95% CI: 0.27–0.66; p=0.0001) Four-year m
  2. FinanceSemtech CorporationSemtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026AirLink 5G Solutions Keep First Responders Connected During Peak Network Demand CAMARILLO, Calif., October 24, 2026--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things ("IoT") devices
  3. FinanceGenmab A/SGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerCompanies: IncytePhase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical tria
  4. FinanceIncyteIncyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal CancerCompanies: IncytePhase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) WILMINGTON, Del. & COPENHAGEN, Denmark, October 24, 2026--Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial c
  5. HealthcareBeOne Medicines Ltd.BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer Brain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient dataset First clinical data of CEA
  6. HealthcareCatalYmCatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026Visugromab combined with PD-1 inhibitor nivolumab demonstrated higher response rates versus nivolumab alone across primary and secondary endpoints: pathologic Complete Response (pCR; 33% vs. 8%), radiographic Objective Response Rate (ORR; 60% vs. 15%) and Major Pathologic Response (MPR; 60% vs. 23%) Enhanced responses wer